RxDoctor Payments Data

Vanessa Wilson, MD

Internal Medicine · Fremont, CANPI 1992728620

Payments from drug & device makers

$1,305in general payments, 2019–2025

Across 8 payments — averaging $163.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • KCI USA, Inc.$774
  • Electromed, Inc.$142
  • AstraZeneca$123
  • Solventum Corporation$97
  • Boston Scientific$93
  • Mallinckrodt Hospital Products Inc.$76

What the payments were for

  • Travel & lodging$44034%
  • Food & beverage$86566%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,305 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$231,712
Medicare patients
356
Services billed
2,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin71$83,726
RybelsusSemaglutide31$70,283
OzempicSemaglutide39$48,765
EliquisApixaban31$43,217
FarxigaDapagliflozin Propanediol31$35,021
MounjaroTirzepatide26$34,712
JanuviaSitagliptin Phosphate16$23,751
Diclofenac Sodium34$11,554
Janumet XrSitagliptin Phos/Metformin Hcl13$8,167
Atorvastatin Calcium549$6,143
MyrbetriqMirabegron12$5,653
SantylCollagenase Clostridium Hist.12$5,641
Wixela InhubFluticasone Propion/Salmeterol24$5,408
Losartan Potassium289$4,712
Ezetimibe92$4,476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$123$35,02131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fremont

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →